Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

  • End date
    Nov 30, 2021
  • participants needed
  • sponsor
    Ludwig-Maximilians - University of Munich
Updated on 23 January 2021
renal function
gilbert's syndrome
b-cell acute lymphoblastic leukemia
cellular therapy
bcr-abl protein


This phase 2 study is designed to evaluate the safety, tolerability and efficacy of allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager blinatumomab in B-precursor ALL patients who have mixed chimerism (MC) or are MRD-positive after allogeneic SCT and are refractory to at least one MRD- or MC-targeted therapy (i.e. blinatumomab, DLI, tyrosine kinase inhibitors or other agents).

Condition childhood ALL, Acute Lymphoblastic Leukemia in Remission, Lymphocytic Leukemia, Acute, B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, acute lymphoblastic leukemia, leukemia, acute lymphoblastic, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
Treatment Blinatumomab in combination with donor lymphocyte infusion
Clinical Study IdentifierNCT03982992
SponsorLudwig-Maximilians - University of Munich
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Acute Lymphoblastic Leukemia in Remission or B-Cell Acute Lymphoblastic Leukemia or childhood ALL or B Cell Precursor Acute Lymphoblastic Leukemia Wit...?
Do you have any of these conditions: B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation or Acute Lym...?
Adult patients with CD19+ B-precursor ALL (as determined by immunophenotyping) in hCR (defined as having less than 5% blasts in bone marrow) after allogeneic SCT
One, or a combination of the following documented after an interval of at least 2 weeks since cessation of the most recent leukemia-targeting therapy (i.e. chemotherapy, immunotherapy or cellular therapy, except for intrathecal prophylaxis)
Positivity for CD19+ MRD (molecular failure or molecular relapse), defined as presence of MRD at a level of 10^-4 according to an assay with a minimum sensitivity of 10^-4
Donor chimerism <90%, as determined by analysis of host and donor STRs in bone marrow sample engraftment analysis
At least one previous line of treatment for MRD-positivity and/or reduced donor chimerism (i.e. blinatumomab, DLI, TKI or other agents) after allogeneic SCT
For those with BCR/ABL-positive B-precursor ALL only: persistence of MRD and/or MC following at least one second generation TKI (dasatinib, nilotinib, bosutinib, ponatinib) OR intolerance to second generation TKI and intolerance to or persistence of MRD and/or MC following imatinib mesylate
Availability of allogeneic donor lymphocytes from the subject's donor (at least 2 x 10^8 T cells/kg)
Subject has provided written informed consent prior to initiation of any study-specific activities/procedures
Subject has provided informed consent to be followed up in the GMALL-Registry
Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Renal function as follows: serum creatinine < 2.0 mg/dL and estimated glomerular filtration rate > 30 mL/min
Hepatic function as follows
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) 3.0 x upper limit of normal (ULN)
Alkaline phosphatase (ALP) < 3.0 x ULN
Bilirubin 2.0 x ULN (unless considered due to Gilbert's syndrome or hemolysis)
For female subjects only: Women of child-bearing age have to use a reliable method of contraception

Exclusion Criteria

Eligibility for treatment with blinatumomab ALONE or other antibody-based treatment approaches (e.g. inotuzumab ozogamicin), as considered by the treating physician
Eligibility for standard chemotherapy, as considered by the treating physician
Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives (whichever is longer) prior to baseline MRD and/or chimerism assessment
Treatment with systemic immune modulators including, but not limited to, non-topical systemic corticosteroids, cyclosporine, and tacrolimus within 2 weeks before enrollment
Any grade of GvHD currently requiring treatment
Clinically relevant central nervous system (CNS) pathology requiring treatment (e.g., unstable epilepsy)
Evidence of current CNS involvement by ALL
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note